Business Wire

The First of Five Architectural Masterpieces at The Case, Malibu’s Only New Guard Gate Community in Decades, Lists for $69.995 Million

16.6.2022 00:51:00 EEST | Business Wire | Press release

Share

After more than a decade in approvals, design, and construction, Scott Gillen, visionary home designer, creator and founder of Unvarnished, has listed for sale the first of five estates in the 24-acre private enclave known as The Case. The first guard gated community built in Malibu in decades, The Case comprises five spectacular mid-century modern inspired homes perched above The Colony on Malibu’s most coveted oceanfront bluff and represents the largest private residential development in its history. The Edge, on the market for $69.995 million, will be the first home completed within the community and will be delivered turnkey, providing the buyer instant gratification of unprecedented luxury and hand-crafted design perfection. All five bespoke homes are currently under construction, with the remaining homes slated for full completion throughout the year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615006048/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Edge (Photo: Business Wire)

“The Case is my largest and most epic project to date. The opportunity to create a community of five homes on one of, if not the best bluff top on the California coast, was something I could not pass up. Frankly, ten minutes after I stepped on the property, I knew I would buy it,” said Scott Gillen, the founder of Unvarnished. “The sheer size of the property and the ability to build 10,000 to 12,000-square foot single story homes created immense challenges and unbelievable opportunities for me to take some of my foundational design principles--use of warm natural materials, a nod toward mid-century modern, large, opened spaces, lots of natural light and blurring the line between indoors and out-- which are also tenets of mid-century modern architecture--to the next level. So, it was natural that my designs for The Edge, and the other homes at The Case, take enormous inspiration from mid-century modern architecture, and then I incorporate construction techniques and furnishings, the quality of which are rarely, if ever, found in new development, to create a unique experience of luxury living on the coast of Malibu, a place unlike anywhere else in the world. I’m very proud of how The Edge has turned out and I’m incredibly excited to bring it to market.”

The 2.6-acre estate, providing cinematic views of the Queen’s necklace, Palos Verdes to Point Dume, embodies the essence of casual luxury living. Spanning approximately 10,500 square feet, the single-story home offers five ensuite bedrooms and three half baths, and includes a Bulthaup chef’s kitchen, expansive great room, a master bedroom with outdoor spa, and floor to ceiling glass doors that open to a 10,000-square foot Ipe deck with cabana and outdoor kitchen.

The Edge, named for its stunning nearly 80-foot double-sided infinity edge freshwater pool that juts out like a diving board into the Pacific Ocean, with famed Catalina Island in the distance, is architecturally inspired by the giants of mid-century modern, Lloyd Wright, Neutra, Lautner and Quincy Jones, to name but a few. The magnificent home also includes hand-picked custom furnishings by Minotti and Gillen, Miele and Gaggenau appliances, custom cabinets, a 650-bottle teak wine room, a glass and teak enclosed private library, and a home theatre that is a room “floating” inside another room to achieve the ultimate home cinema experience.

The Case is the crown jewel of Scott Gillen’s visionary Malibu Series, where each home is a sanctuary unto itself. Behind its 24-hour manned guard gate and security features designed by international renowned security expert Gavin de Becker, residents of The Case will live with ultimate peace of mind and privacy.

The Case comprises five distinct mid-century modern homes: The Cantilever House (Case Study No. 1), The Butterfly House (Case Study No. 2), The Edge (Case Study No. 3), The Flat House (Case Study No. 4) and The Glass Tunnel (Case Study No. 5).

For more information, visit www.unvarnishedco.com or contact listing agent Sandro Dazzan of The Agency.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Emily Warner
Murphy O’Brien Public Relations
unvarnishedcopr@murphyobrien.com 
310.453.2539

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye